Research programme: aurora kinase inhibitors - AstraZeneca
Alternative Names: Compound 677; ZM 447439Latest Information Update: 22 Jan 2008
At a glance
- Originator AstraZeneca
- Class Quinazolines
- Mechanism of Action Aurora kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Haematological malignancies
Most Recent Events
- 16 Jan 2006 Preclinical trials in Haematological malignancies in United Kingdom (unspecified route)
- 16 Jan 2006 Data presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH-2005) have been added to the Cancer pharmacodynamics section
- 07 Jul 2004 Data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been added to the Cancer pharmacodynamics section